Loading...

Theralink

BEYOND GENOMICS

BEYOND GENOMICS

Protein drug target activation mapping to change the paradigm in precision medicine based cancer therapy

Presentation by
Avant Diagnostics (whose corporate name has been changed to Theralink Technologies, Inc.) on Theralink’s Reverse
Phase Protein Array (RPPA) Technology.

ENABLING PHYSICIANS TO HELP MAKE PERSONALIZED TREATMENT RECOMMENDATIONS FOR CANCER PATIENTS

ENABLING PHYSICIANS TO HELP MAKE PERSONALIZED TREATMENT RECOMMENDATIONS FOR CANCER PATIENTS

Theralink may enable clear decision making for an individual patient’s cancer treatment using protein biomarkers.

LEARN MORE

EARLY AND LATE STAGE DRUG DEVELOPMENT

EARLY AND LATE STAGE DRUG DEVELOPMENT

FOR BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES

Theralink biopharma services will help drug companies accelerate their drug discovery programs.

Preclinical

Evaluate the on-target and off-target effects of your drug in our laboratory with the latest technologies

Companion Diagnostic

Partner with Theralink Technologies to maximize the potential of your therapeutics

Clinical

Utilize our technology to stratify patients as potential responders/non responders in your clinical trials

Ask a Proteomic Scientist

Talk to one of our team members on how Theralink Technologies can assist you
LEARN MORE

WE’LL ENSURE YOU ALWAYS RECEIVE
OPTIMAL DATA.

WE’LL ENSURE YOU ALWAYS RECEIVE
OPTIMAL DATA.

600

Protein targets

Our RPPA technology can evaluate over 600 different protein and phosphoprotein targets

1000+

Peer-reviewed publications

Our company builds upon 1000+ peer-reviewed publications using the RPPA technology to advance precision medicine

7

Scientific patents

Our services are supported by seven patents covering the RPPA technology and the phosphoproteome

WHAT PEOPLE SAY ABOUT OUR TESTS

WHAT PEOPLE SAY ABOUT OUR TESTS

Joyce O’Shaughnessy, M.D.

Texas Oncology
The Theralink assay allows me to understand which protein biomarkers and signaling pathways are active and driving my patient’s metastatic breast cancer growth. Proteomic information can be instrumental in helping guide therapy choices for my patients.

Brian Leyland-Jones

BSc (Hons), MB BS, PhD, FACP, FCRCP
We use the Theralink assay on every possible occasion, in combination with targeted sequencing, to guide the choice of matched targeted therapies. The assay is extremely beneficial to our patients, in terms of adding proteomic expression data, over and above DNA sequencing

INVEST IN THERALINK: THE FUTURE OF PRECISION MEDICINE

INVEST IN THERALINK: THE FUTURE OF PRECISION MEDICINE

INVESTOR RELATIONS

REQUEST MORE INFORMATION